BerandaEVGN • NASDAQ
add
Evogene Ltd
$1,62
Setelah Jam Perdagangan Normal:(7,41%)-0,12
$1,50
Tutup: 22 Nov, 20.00.00 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$1,60
Rentang hari
$1,52 - $1,67
Rentang tahun
$1,44 - $10,40
Kapitalisasi pasar
8,19Â jt USD
Volume Rata-Rata
556,08Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | 1,80Â jt | -52,32% |
Biaya operasional | 8,17Â jt | 9,83% |
Laba bersih | -7,63Â jt | -91,52% |
Margin laba bersih | -424,83 | -301,69% |
Penghasilan per saham | -1,31 | -63,75% |
EBITDA | -6,83Â jt | -93,87% |
Tarif pajak efektif | -0,01% | — |
Neraca
Total aset
Total liabilitas
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 19,95Â jt | -46,40% |
Total aset | 40,11Â jt | -30,53% |
Total liabilitas | 27,88Â jt | 27,39% |
Total ekuitas | 12,24 jt | — |
Saham yang beredar | 6,79 jt | — |
Harga terhadap nilai buku | -2,50 | — |
Tingkat pengembalian aset | -45,97% | — |
Tingkat pengembalian modal | -110,69% | — |
Arus Kas
Perubahan kas bersih
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | -7,63Â jt | -91,52% |
Kas dari operasi | -4,93Â jt | -14,15% |
Kas dari investasi | 2,02Â jt | -44,68% |
Kas dari pembiayaan | 4,73Â jt | -39,30% |
Perubahan kas bersih | 1,83Â jt | -74,18% |
Arus kas bebas | 757,88Â rb | 124,92% |
Tentang
Evogene is a computational biology company based in Israel. Evogene Ltd. has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence, while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficiency and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF, Bayer, Corteva, ICL Group Ltd. as well as various academic and medical institutions. Wikipedia
CEO
Didirikan
2002
Situs
Karyawan
142